Clinical trials: Prostate Adenocarcinoma, open to volunteers
Prostate Cancer (Adenocarcinoma)
Dose De-escalation in Prostate Radiotherapy Using an MR-Linac in Two Fractions
The goal of this clinical trial is to find out whether lowering the radiation dose to parts of the prostate without visible tumor on MRI can reduce side effects while still effectively treating prostate cancer in men with low or…
- Trial name
- DESTINATION 2 (NCT07391982)
- Testing
- uniform dose radiotherapy, De-escalated dose radiotherapy
- Where
- Netherlands
- Volunteers
- 54 people
- Sponsor
- The Netherlands Cancer Institute
Prostate CA, Prostate Cancer (Adenocarcinoma)
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
The goal of this clinical trial is to determine the safety and feasibility of a new combination of darolutamide and relugolix as neoadjuvant therapy preceding radical prostatectomy (RP) for high-risk prostate cancer (PCa) in…
- Conditions
- Prostate CA, Prostate Cancer (Adenocarcinoma), Prostate Cancer Surgery
- Trial name
- NCT06631521
- Testing
- Darolutamide, Relugolix, Radical Prostatectomy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- AdventHealth
Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8
Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial
This clinical trial studies the side effects of image-guidance and online adaptation with stereotactic body radiation therapy (SBRT) for the treatment of patients with prostate adenocarcinoma that has not spread to other parts of…
- Conditions
- Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
- Trial name
- NCT07276438
- Testing
- Biospecimen Collection, Computed Tomography, CT-guided Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 186 people
- Sponsor
- Jonsson Comprehensive Cancer Center
mHSPC, mHNPC
Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer
This study is a single-centre, randomised, paired 24-week intervention dosing trial. Its purpose is to evaluate the safety profile and efficacy of the investigational drug in subjects with metastatic hormone-sensitive prostate…
- Conditions
- mHSPC, mHNPC, Prostate Cancer Adenocarcinoma
- Trial name
- NCT07389174
- Testing
- Standard Endocrine Therapy, LC-K76
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Changzheng Hospital
Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation.
- Conditions
- Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
- Trial name
- NCT05806515
- Testing
- Biospecimen Collection, Carboplatin, Chest Radiography
- Where
- 133 sites in United States
- Volunteers
- 44 people
- Sponsor
- SWOG Cancer Research Network
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
This phase II trial studies the effect of talazoparib with androgen deprivation therapy and abiraterone in treating castration sensitive prostate cancer patients.
- Conditions
- Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT04734730
- Testing
- Abiraterone Acetate, Bicalutamide, Degarelix
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- City of Hope Medical Center
Prostate Cancer (Adenocarcinoma)
LUtetium-177 DOsimetry as a Predictive Biomarker of Response in Metastatic Prostate Cancer Patients Treated With PSMA Radioligand THerapy.
A substantial proportion of patients with mCRPC do not respond to 177Lu-PSMA-RLT. The PSA response to Lu-PSMA was observed in nearly 46% of patients included in VISION trial and 66% in LuPSMA trial (4,5).
- Trial name
- LUDOPATH (NCT07370597)
- Where
- Belgium
- Volunteers
- 110 people
- Sponsor
- Jules Bordet Institute
Prostate Cancer (Adenocarcinoma)
The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer
The gastrin-releasing peptide receptor (GRPR) is highly expressed in prostate cancer (77%-100%). Numerous studies have confirmed that GRPR PET imaging has emerged as a significant molecular imaging modality in prostate cancer…
- Trial name
- NCT07363382
- Testing
- 68Ga-G21, 68Ga-G23
- Where
- China
- Volunteers
- 6 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Prostate Cancer (Adenocarcinoma)
Adaptive Stereotactic Radiotherapy for Localized Prostate Cancer
This study evaluates whether adaptive stereotactic body radiotherapy (SBRT) provides dosimetric advantages compared to non-adaptive SBRT in localized prostate cancer.
- Trial name
- SPAR (NCT07344844)
- Testing
- Low-dose CT imaging before each SBRT session
- Where
- Reunion
- Volunteers
- 100 people
- Sponsor
- Clinique Sainte Clotilde
Prostate Cancer (Adenocarcinoma)
Navigation, Outcomes and Quality-of-life in Prostate Cancer Patients Undergoing PSMA-targeted Surgery
As part of a feasibility study, it's planned to use a 3D virtual mixed reality model with prostate cancer patients who show signs of lymph node metastasis and are scheduled for surgery.
- Trial name
- NICE-PSMA (NCT07129551)
- Testing
- preop virtual 3D model, postop 3D model
- Where
- 2 sites in Germany
- Volunteers
- 102 people
- Sponsor
- Martini-Klinik am UKE GmbH
Triple Negative Breast Cancer, HER2-negative Breast Cancer
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas
- Conditions
- Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer
- Trial name
- NCT06999187
- Testing
- DR-0202
- Where
- 10 sites in United States
- Volunteers
- 96 people
- Sponsor
- Dren Bio
Prostate Adenocarcinoma
Personalized Optimization of Systematic Prostate Biopsy
Targeted biopsy combined systematic biopsy is the gold standard for diagnosis of prostate cancer. Excessive cores in systematic biopsy increases the risk of puncture trauma， bleeding and infection.
- Trial name
- NCT05998278
- Testing
- Personalized Optimization of Systematic Prostate Biopsy
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Fujian Medical University Union Hospital
Prostate Cancer, Prostate Adenocarcinoma
Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement
This purpose of this study is to examine the placement of proton spots during pencil beam scanning proton therapy for low and intermediate risk prostate cancer.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Carcinoma
- Trial name
- NCT06200259
- Testing
- Spot Delete planning for proton therapy, Traditional proton treatment planning system
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Covenant Health Cancer Center
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC)
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer
- Trial name
- NCT06943521
- Testing
- MT-4561
- Where
- 6 sites in United States, Japan
- Volunteers
- 27 people
- Sponsor
- Tanabe Pharma America, Inc.
Metastatic Prostate Cancer, Prostate Cancer (Adenocarcinoma)
CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer
This is a prospective, randomized, open-label, phase II multicenter clinical trial evaluating the efficacy and safety of radical prostatectomy in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) who…
- Conditions
- Metastatic Prostate Cancer, Prostate Cancer (Adenocarcinoma), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Trial name
- CONVERT-HB1 (NCT07268794)
- Testing
- Androgen Deprivation Therapy (ADT), Docetaxel, PARP Inhibitors and Other Systemic Agents
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Fudan University
Prostate Adenocarcinoma
Neoadjuvant Embolization and Cytoreduction in Prostate Cancer
The goal of this clinical trial is to find out whether prostate artery embolization (PAE) can help prevent or lessen urinary side effects caused by radiotherapy (RT) in people with prostate cancer, especially those who have…
- Trial name
- NCT07251829
- Testing
- Prostatic Artery Embolization
- Volunteers
- 35 people
- Sponsor
- Srinivas Raman
Prostate Cancer (Adenocarcinoma)
Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer
The goal of this clinical trial is to evaluate if adaptive stereotactic body radiation therapy (SBRT) is a safe and effective way to treat prostate cancer in adults. It will assess the safety profile of adaptive SBRT over time.
- Trial name
- DE-CART (NCT07219303)
- Testing
- adaptive stereotactic body radiation therapy (SBRT) with a SIB
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Fox Chase Cancer Center
Prostate Cancer, Prostate Adenocarcinoma
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
This study will follow men with metastatic castration resistant prostate cancer throughout their standard of care treatment for their disease to determine if the presence of different genes or proteins can predict which patients…
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
- Trial name
- ARCTIC (NCT06141993)
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Duke University
Prostate Cancer (Adenocarcinoma)
68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI
68Ga-PSMA-11 is a widely used radiotracer targeting PSMA. In this study, we investigated the diagnostic efficacy of 68Ga-PSMA-11 PET imaging (PET/CT or PET/MRI) in patients with newly diagnosed, treatment-naive prostate cancer…
- Trial name
- NCT07209878
- Testing
- 68Ga-PSMA-11
- Where
- China
- Volunteers
- 100 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Prostate Adenocarcinoma
Side Effects of Low Dose Rate Brachytherapy and Ultra-hypofractionated Radiotherapy in Low to Intermediate Risk Prostate Cancer
The LDR BURST trial will compare the side effects of two radiotherapy treatments for men with localised prostate cancer. The first treatment is 4D low dose rate brachytherapy where small radioactive seeds are inserted into the…
- Trial name
- LDR BURST (NCT07210502)
- Testing
- 4D Low Dose Rate Prostate Brachytherapy, Ultra-hypofractionated Radiotherapy
- Where
- United Kingdom
- Volunteers
- 220 people
- Sponsor
- Royal Surrey County Hospital NHS Foundation Trust